Keywords
rheumatoid arthritis
antiphospholipid antibodies
How to Cite
Abstract
The antiphospholipid syndrome (APS) is an autoimmune disease characterized by vascularthrombosis, recurrent abortions and persistent elevation of antiphospholipid antibodies. Since its first description in 1983, a wide variety of dermatological manifestations have been associated with this syndrome, most frequently livedo reticularis and skin ulcers. The presence of antiphospholipid antibodies has been described in several diseases such as autoimmune diseases, infections, neoplasms and secondarily to the use of certain drugs. We report the case of a 72-year-old diagnosed with Rheumatoid Arthritis and secondary APS, for its unusual relationship.References
(1) Marini M, Rossi G, Magariños G. Síndrome antifosfolipídico: presentación de un caso y actualización del tema. Med Cutan Iber Lat Am 2002;30(5):111-5.
(2) Lashak C, Leroux MB. Anticuerpos antifosfolípidos: Valoración clínica actual. Arch. Argent. Dermatol. 2009, 59:107-113.
(3) García Rincón CI, Morales Restrepo N, Muñoz-Grajales C, Cardozo Avendaño SL, Calle J, Velazquez Franco CJ et al. Necrosis cutánea extensa secundaria a síndrome antifosfolípido en un paciente con infección por el virus de la inmunodeficiencia humana: reporte de caso. Rev Colomb Reumatol. 2014; 21(3):155-159.
(4) García-García C. Anticuerpos antifosfolípido y síndrome antifosfolípido: actitudes diagnósticas y terapéuticas. Actas Dermosifiliogr. 2007; 98:16-23.
(5) Barraza S, Estrella V, Leroux MB et al. Síndrome anticuerpo antifosfolípido. ¿Cómo llegamos a su diagnóstico? Dermat Argent 2000; 6: 342-349.
(6) Leroux MB, Barraza S, Estrella V y Bearzotti M. Síndrome anticuerpo antifosfolípido. Arch Argent Dermatol. 2000; 50:109-115.
(7) Shoenfeld Y, Meroni P, Cervera R. Antiphospholipid syndrome dilemmas still to be solved: 2008 status. Ann RheumDis. 2008; 67: 438-442.
(8) Alfaro R. Síndrome antifosfolipídico, revisión bibliográfica. Rev Médica C osta Rica y Centroamérica. 2009; 66 (589): 313-317.
(9) O mar P, Yalili C, Iarmila C. Síndrome de anticuerpos antifosfolípidos. MEDISAN 2012; 16(3):429-444.
(10) Uthman IW, Khamashta MA. Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome. J Rheumatol. December 2006; 33(12):2379-2382.
(11) R odríguez Santamaría J, Badziak D, Ferreirade Barros M, Luiz Mandelli F, Cavalin LC, Shigueru Sato M. Síndrome antifosfolípide. An Bras Dermatol. 2005; 80(3): 3-4.
(12) Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R. International consensus statement on an update of the classification criteria for definitive antiphospholipid syndrome. J Thromb Haemost
; 4 (2): 295-306.
(13) C ontreras M. Inmunopatogenia del sindrome antifosfolipídico. Rev. chil. reumatol. 2009; 25(4):149-155.
(14) Lim W. Antiphospholipid syndrome. Hematology 2013:675-80.
(15) Cuadrado MJ, Bertolaccini ML, Seed PT, et al. Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). R heumatology 2014;53:275-84.